Merck stock holds firm as Q2 sales hit $16.61 billion
Published on 08/19/2026 at 06:58 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS
Merck & Co. (US58933Y1055) is trading near $135 after a session that put the shares at $137.98 on the high side and $134.88 on the low side, with market value readings above $333 billion on August 19, 2026. The latest quarterly update showed $16.61 billion in revenue, a $0.13 loss per share, and FY 2026 EPS guidance of 2.660 to 2.760.
Revenue still carries the story
The second-quarter revenue figure was reported as $16.61 billion, up 5.1% year over year, and it came in above the $16.37 billion consensus estimate. That gap matters because it shows the top line is still expanding even as the company posted a per-share loss for the quarter.
Another detail stands out: the same report showed a revenue base that was larger than a year earlier by 5.1%, while the earnings line improved versus the consensus loss of $0.26 per share by $0.13. For investors, that combination keeps the focus on execution rather than on a single quarter's bottom-line miss.
Guidance stays in view
FY 2026 guidance was set at 2.660 to 2.760 EPS, while analysts in the same coverage set expect 2.77 EPS for the current year. That puts the company close to the market's earnings view, but still below the average estimate in that snapshot.
Valuation also frames the debate. One market snapshot put Merck at a $333.49 billion market cap and a P/E ratio of 108.68, while a separate view showed the shares near the top of their intraday range and only 2.2% below the session high.
What the numbers say
Within the current print, the key change is simple: revenue rose to $16.61 billion from the prior-year quarter, and EPS improved by $0.13 versus the estimate. That is the kind of quantified comparison traders can anchor on while the stock stays close to its recent range.
Analyst sentiment in the same market set was constructive, with a consensus target price of $135.50 and a Moderate Buy label attached to the stock. The target sits close to the current trading zone, which keeps attention on whether earnings can justify the current valuation.
Keytruda still matters
The company remains tied to Keytruda, its best-known oncology product and a core driver of its revenue mix. In the quarter, the broader business still produced enough sales to keep the company within range of full-year guidance, even with the loss reported on an EPS basis.
That product mix matters because investors are not just watching one quarter's numbers. They are watching whether Merck can keep turning a $16.61 billion sales base into steadier earnings traction.
Shares and setup
Merck stock is priced at $135.01 as of August 19, 2026, with a market capitalization of $333.49 billion, a daily high of $137.98, a daily low of $134.88, and volume of 10.28 million shares. The stock is trading close to the top of its recent intraday span, but the earnings gap still leaves room for debate.
Fact box
Company: Merck & Co., Inc.
ISIN: US58933Y1055
Ticker: MRK
Exchange: NYSE
Price (as of August 19, 2026, 4:13 a.m. ET): $135.01 USD
Market cap: $333.49 billion (as of August 19, 2026)
Sector / Industry: Health Care / Pharmaceuticals
More on Merck stock
Merck's product mix still leans heavily on oncology, vaccines, and animal health, with Keytruda acting as the most visible revenue anchor in the public investor narrative. That makes the next earnings discussion less about one line item and more about whether the company can keep combining scale, margin discipline, and pipeline contribution.
Investor relations
Merck stock stays supported by a large market cap, a $16.61 billion quarter, and FY 2026 EPS guidance of 2.660 to 2.760. At $135.01, the shares are priced for continued execution.
